D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

NCT ID: NCT06622057

Last Updated: 2025-04-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 195 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-01
• Study Completion Date: 2027-12-31

Brief Summary

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).

Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.

Detailed Description

This is a Phase III, randomized, double-blind, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of D07001-softgel capsules + capecitabine tablets in participants with advanced BTC after failure on an intravenous gemcitabine and cisplatin-based, and also failed on or refused FOLFOX or failed on irinotecan and fluorouracil regimen. Approximately 195 participants (approximately 65 per treatment arm) will be randomized 1:1:1 to one of the following treatment arms:

• Oral D07001 softgel capsules, 100 mg/day + capecitabine tablets (1000 mg/m2 twice daily [bid])
• Oral D07001 softgel capsules, 60 mg/day + capecitabine tablets (1000 mg/m2 bid)
• Oral placebo softgel capsules + capecitabine tablets (1000 mg/m2 bid) A formal interim futility analysis will be conducted when approximately 80 participants have either experienced disease progression or death. Study participants will continue study treatment until unacceptable toxicity, disease progression, death, withdrawal of consent to treatment, or completing 12 treatment cycles, whichever comes first. The EOT Visit will occur following unacceptable toxicity, disease progression, completing 12 treatment cycles or withdrawal of consent to treatment. Follow-up Period/Visits over phone call will be conducted for participants on 30 ± 3 days, every month; and at 365 ± 3 days following the EOT Visit.

Conditions

Biliary Tract Cancer (BTC)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

D07001-Softgel Capsules 60 mg + Capecitabine

• D07001-softgel capsules, 60 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)
• Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

Group Type: EXPERIMENTAL

D07001-Softgel Capsules

Intervention Type: DRUG

D07001-softgel capsule is an oral gemcitabine.

Capecitabine

Intervention Type: COMBINATION_PRODUCT

Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

D07001-Softgel Capsules 100 mg + Capecitabine

• D07001-softgel capsules, 100 mg/day, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)
• Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

Group Type: EXPERIMENTAL

D07001-Softgel Capsules

Intervention Type: DRUG

D07001-softgel capsule is an oral gemcitabine.

Capecitabine

Intervention Type: COMBINATION_PRODUCT

Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Placebo + Capecitabine

• Placebo, orally 3 times per week before lunch (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle)
• Capecitabine tablets (1000 mg/m2 bid) for 14 days (on Days 1 through 14 of a 21 day cycle) followed by a 7-day rest period. Capecitabine will be taken after breakfast and after dinner.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)

Capecitabine

Intervention Type: COMBINATION_PRODUCT

Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Interventions

D07001-Softgel Capsules

D07001-softgel capsule is an oral gemcitabine.

Intervention Type: DRUG

Placebo

Placebo has the same excipient with D07001-softgel but without active pharmaceutical ingredients (APIs)

Intervention Type: DRUG

Capecitabine

Capecitabine, a fluoropyrimidine carbamate derivative, is an oral tumor activator and selective cytotoxic agent.

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

1. Provide written informed consent prior to any study procedures and agree to adhere to all protocol requirements

2. Aged at least 18 years.

3. Has histopathological or cytologic diagnosis of unresectable, locally advanced or metastatic BTC.

4. Has measurable disease as assessed by RECIST v1.1.

5. Must have failed on a gemcitabine + cisplatin-based chemotherapy, regardless of whether immune checkpoint inhibitor, such as durvalumab or pembrolizumab, or S-1 (tegafur, gimeracil, and oteracil potassium), was also administered. Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern. Participants also have failed (disease progression or intolerance) on, or refused FOLFOX chemotherapy, including modified FOLFOX variants, or failed on or irinotecan + fluorouracil chemotherapy.

6. Participants with tumors expressing the following biomarkers can be enrolled if they have not previously received FOLFOX but have received appropriate targeted therapies until disease progression or intolerance: fibroblast growth factor receptors aberrations, microsatellite instability biomarker/deficient DNA mismatch repair, or isocitrate dehydrogenase mutations.

7. ECOG PS of 0-2.

8. Life expectancy is ≥12 weeks.

9. Has adequate bone marrow function, demonstrated by: (a) ANC ≥1500 cell/mm3; (b) Platelet count ≥85,000 cells/mm3; (c) Hemoglobin ≥9 g/dL.

10. Has adequate liver function, demonstrated by: (a) AST and ALT ≤2.5 × ULN, or ≤5.0 × ULN in the case of liver lesions; (b) Total bilirubin ≤1.5 × ULN; (c) Albumin ≥3.0 g/dL; (d) INR <1.5.

11. Has adequate renal function, demonstrated by CCR ≥ 45 mL/min or eGFR ≥ 45 mL/min/1.73 m2

12. No clinically significant abnormalities in coagulation results.

13. Participant is eligible to participate if not pregnant (as demonstrated by serum pregnancy testing at screening), not breastfeeding, and at least 1 of the following conditions applies:

1. Not of childbearing potential (CBP).

2. A participant of CBP who is sexually active with a partner who could impregnate them agrees to use a highly effective form of contraception during the study and for at least 30 days after the end of study intervention.

14. With partners of childbearing potential whom they could impregnate must agree to use contraception during the study and for 90 days after the end of study intervention.

15. Participants who are able to donate sperm must refrain from sperm donation during the study and for 90 days after the end of study intervention.

16. Participant is willing to comply with the protocol-required visit schedule and visit requirements.

17. More than 14 days have elapsed between the participant completing a prior line of chemotherapy or target therapy, and enrollment. More than 28 days have elapsed between the participant receiving concurrent radiotherapy (CCRT) and enrollment.

Exclusion Criteria

1. Has a diagnosis of active malignancy other than BTC within the past 2 years, except nonmelanoma skin carcinoma and carcinoma-in-situ of uterine cervix treated with curative intent.

2. Participant discontinued prior gemcitabine due to pulmonary or hepatic toxicity or hemolytic uremic syndrome, hypersensitivity, allergic reaction, or intolerance.

3. Participant had a prior unanticipated severe reaction to capecitabine or metabolites or to fluoropyrimidine therapy.

4. Participant received treatment with brivudine, sorivudine, or its chemically related analogs ≤28 days prior to the date of enrollment.

5. Participant is currently receiving flucytosine treatment.

6. Participant has residual toxicity from prior chemotherapy or CCRT that is Grade ≥2 (residual Grade 2 neuropathy and alopecia are permitted).

7. Participant has any gastrointestinal disorder or prior gastrointestinal surgery that would significantly impede absorption of an oral agent, such as gastrectomy, Crohn's disease, ulcerative colitis, or short gut syndrome.

8. Participant has known brain or leptomeningeal metastases.

9. Participant had major surgery or definitive ablation-intent (excluding palliative radiotherapy for bone metastasis) radiation therapy within the past 28 days.

10. Participant has any active disease or condition that would not permit compliance with the protocol.

11. Participant has clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, congestive heart failure, New York Heart Association Grade 2 or greater), or uncontrolled serious cardiac arrhythmia.

12. Participant has documented cerebrovascular disease.

13. Participant has a seizure disorder not controlled with medication (based on Investigator's decision).

14. Participant has received an investigational agent within 28 days of enrollment.

15. Participant has an uncontrolled active viral, bacterial, or systemic fungal infection.

16. Participant has positive hepatitis B surface antigen with positive hepatitis B virus DNA ≥2000 copies/mL and/or anti-hepatitis C virus antibody.

17. Participant has received yellow fever vaccine or other live attenuated vaccine(s) within the 4 weeks before screening.

18. Participant has a history of drug or alcohol abuse within the year before signing the informed consent form.

19. Participant has any other serious medical condition that, in the Investigator's medical opinion, would preclude safe participation in or compliance with the clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InnoPharmax Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andy Huang

Role: STUDY_DIRECTOR

InnoPharmax Inc.

Locations

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Countries

Taiwan

Central Contacts

Yuyuan Lin

Role: CONTACT

yuan.lin@innopharmax.com

886-287977607 ext. 211

Facility Contacts

Li-Tzong Chen, M.D.

Role: primary

886-73121101

Other Identifiers

Inno-GO-07

Identifier Type: -

Identifier Source: org_study_id